Tuesday, January 31, 2017

AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch

Aeterna Zentaris Inc. has completed its phase III trial of Zoptrex in women with advanced, metastatic endometrial cancer.

from RTT - Biotech http://ift.tt/2kJR55k
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)